人民财讯8月14日电，百普赛斯（301080）8月14日晚间公告，公司实控人之一致行动人苗景赟、上海百 普赛斯、上海百普嘉乐及公司副总经理、董事会秘书、财务负责人林涛计划自9月5日至12月4日期间， 以集中竞价或大宗交易方式减持公司股份。其中，苗景赟计划减持不超过40万股(占总股本0.24%)，上 海百普赛斯和上海百普嘉乐合计拟减持不超过460万股(占总股本2.74%)，林涛计划减持不超过9.45万股 (占总股本0.06%)。 ...

百普赛斯公告，实际控制人一致行动人苗景赟计划2025年9月5日至2025年12月4日以集中竞价或大宗交 易方式减持不超过40万股，占公司总股本0.24%；员工持股平台上海百普赛斯、上海百普嘉乐同期合计 减持不超过460万股，占公司总股本2.74%；副总经理林涛同期减持不超过94500股，占公司总股本 0.06%。 ...

证券代码：301080 证券简称：百普赛斯 公告编号：2025-048 北京百普赛斯生物科技股份有限公司 关于实际控制人之一致行动人及高级管理人员减持股份 的预披露公告 公司实际控制人之一致行动人苗景赟先生、上海百普赛斯企业管理咨询合 伙企业（有限合伙）、上海百普嘉乐企业管理咨询合伙企业（有限合伙）及高 级管理人员林涛先生保证向本公司提供的信息内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一 致。 特别提示： 1、苗景赟先生是北京百普赛斯生物科技股份有限公司（以下简称"公司" 或"发行人"）的实际控制人陈宜顶先生之一致行动人。苗景赟先生（持有公司 股份 14,990,749 股，占公司总股本的 8.93%，占公司剔除回购专用账户中股份数 量后股份总数的 8.96%）计划自本减持计划公告之日起 15 个交易日之后的 3 个 月内（自 2025 年 9 月 5 日至 2025 年 12 月 4 日）以集中竞价或大宗交易方式减 持所持有的公司股份合计不超过 400,000 股（占公司总股本的 0.24%，占公司剔 除回购专用账户中股份数量后 ...

证券日报网讯8月4日晚间，百普赛斯（301080）发布公告称，截至2025年7月31日，公司通过股份回购 专用证券账户以集中竞价交易方式累计回购股份数量为532，700股，占公司总股本的0.3174%。 ...

2024年1至12月份，百普赛斯的营业收入构成为：研究和试验发展占比98.13%，其他业务占比1.87%。 （文章来源：每日经济新闻） 百普赛斯（SZ 301080，收盘价：55.59元）8月4日晚间发布公告称，截至2025年7月31日，公司通过股 份回购专用证券账户以集中竞价交易方式累计回购股份数量约为53万股，占公司总股本的0.3174%，最 高成交价为54.27元/股，最低成交价为41.82元/股，成交总金额约为2561万元。 ...

格隆汇8月4日丨百普赛斯(301080.SZ)公布，截至2025年7月31日，公司通过股份回购专用证券账户以集 中竞价交易方式累计回购股份数量为53.27万股，占公司总股本的0.3174%，最高成交价为54.27元/股， 最低成交价为41.82元/股，成交总金额为2560.60万元(不含交易费用)。 ...

证券代码：301080 证券简称：百普赛斯 公告编号：2025-047 北京百普赛斯生物科技股份有限公司 二、其他说明 关于回购公司股份的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 北京百普赛斯生物科技股份有限公司（以下简称"公司"或"本公司"）于 2024 年 8 月 29 日召开第二届董事会第八次会议，并于 2024 年 9 月 20 日召开 2024 年第一次临时股东大会审议通过了《关于回购公司股份方案的议案》，同意 公司使用自有资金以集中竞价交易方式回购公司部分已发行的人民币普通股股 份，用于注销并相应减少公司注册资本。本次回购资金总额不低于人民币 2,000 万元（含）且不超过人民币 4,000 万元（含），回购价格不超过人民币 50.00 元 /股（含），回购实施期限为自公司股东大会审议通过本次回购股份方案之日起 12 个月内。具体内容详见公司分别于 2024 年 8 月 30 日、2024 年 9 月 20 日在巨潮 资讯网（www.cninfo.com.cn）披露的《关于回购公司股份方案的公告》（公告编 号：2024-026）和《 ...

Group 1 - The stock price of Baipusais experienced volatility on July 30, opening at 57.01 yuan, dropping to a low of 54.72 yuan, and closing at 55.41 yuan, a decrease of 2.21% from the previous trading day [1] - During the trading session, there was a rapid rebound, with the stock price increasing over 2% within 5 minutes at 9:37 AM, reaching 57.27 yuan [1] - On July 30, the net outflow of main funds was 1.583 million yuan, accounting for 0.02% of the circulating market value, with a trading volume of 41,500 lots and a transaction amount of 233 million yuan [1] Group 2 - Baipusais is a company focused on the biopharmaceutical sector, primarily engaged in the research, development, production, and sales of recombinant proteins and other biological products [1] - The company's products are mainly applied in drug research and development, as well as vaccine production [1]

Core Viewpoint - The biopharmaceutical sector experienced a notable increase of 1.77% on July 29, with San Yuan Gene leading the gains, reflecting positive market sentiment in this industry [1]. Group 1: Market Performance - The Shanghai Composite Index closed at 3609.71, up by 0.33%, while the Shenzhen Component Index closed at 11289.41, up by 0.64% [1]. - Key stocks in the biopharmaceutical sector showed significant price increases, with San Yuan Gene rising by 20.76% to a closing price of 34.84, and Nuo Si Lan De increasing by 11.14% to 25.25 [1]. Group 2: Trading Volume and Value - San Yuan Gene had a trading volume of 143,900 shares, resulting in a transaction value of approximately 483 million yuan [1]. - Other notable stocks included Kang Chen Pharmaceutical with a closing price of 60.15, a rise of 7.93%, and a trading volume of 143,600 shares, leading to a transaction value of about 841 million yuan [1]. Group 3: Capital Flow - The biopharmaceutical sector saw a net inflow of 1.341 billion yuan from institutional investors, while retail investors experienced a net outflow of 1.318 billion yuan [2]. - The capital flow data indicates that institutional investors are showing confidence in the sector, while retail investors are withdrawing funds [2][3].

Investment Rating - The report maintains a positive outlook on innovative drugs and the industry chain, recommending continuous attention to this sector [1][5][24]. Core Viewpoints - The report highlights the sustained high prosperity of innovative drugs, with a focus on companies likely to see a revaluation, such as Jiangsu Heng Rui Medicine, Hansoh Pharmaceutical Group, 3SBio, and Huadong Medicine. It also emphasizes Biopharma/Biotech companies with innovative pipelines entering a growth phase, including PATEO, Innovent Biologics, BeiGene, and others [1][5][24]. - The A-share pharmaceutical sector outperformed the market in the third week of July 2025, with a 4.0% increase compared to a 0.7% rise in the Shanghai Composite Index. The report notes that the premium of the pharmaceutical sector relative to all A-shares is currently at a normal level of 86.8% [7][25][16]. - The Hong Kong pharmaceutical sector showed outstanding performance, with the Hang Seng Healthcare index rising by 12.0% and the Hong Kong Biotechnology index increasing by 13.6% during the same period [21][25]. Summary by Sections 1. Continuous Focus on Innovative Drugs and Industry Chain - The report emphasizes the ongoing high demand for innovative drugs and recommends companies such as Heng Rui Medicine, Hansoh Pharmaceutical, and others for potential investment [1][5][24]. 2. Performance of A-Shares Pharmaceutical Sector - In the third week of July 2025, the A-share pharmaceutical sector led with a 4.0% increase, outperforming the overall market. Notable sub-sectors included chemical raw materials and chemical preparations, with gains of 7.0% and 6.8% respectively [7][11][25]. 3. Performance of Hong Kong and U.S. Pharmaceutical Sectors - The Hong Kong pharmaceutical sector performed exceptionally well, with significant gains in the Hang Seng Healthcare and Biotechnology indices. In contrast, the U.S. pharmaceutical sector underperformed, with a decline of 2.5% in the S&P 500 Healthcare Select Sector [21][25].